Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The pivotal phase 3 RAPID trial demonstrated a significant clinical advantage with a conversion rate of 64% for etripamil compared to 31% for placebo (hazard ratio 2.62; p<0.0001). This evidence is supported by a robust statistical analysis and a clear primary endpoint, although earlier phase trials showed mixed results.
Cost effectiveness
No published cost-utility analyses or ICER estimates were identified, and the available budget impact model lacks transparency and empirical validation, leading to a conclusion of non-cost-effectiveness.
Quality of life
While some secondary outcomes reported improvements in treatment satisfaction using the TSQM-9, there were no validated utility measures (like EQ-5D) identified for QALY calculations, indicating a lack of comprehensive HRQoL data.
Supporting Domains
Safety and Adverse Effects
The safety profile of etripamil is favorable, with 50% of patients experiencing mild/moderate adverse events, primarily localized nasal reactions, and no serious adverse events reported in the pivotal trial.
Comparator Selection
The pivotal trials used placebo as a comparator, which is methodologically sound for efficacy estimation but does not provide direct comparative data against standard acute therapies like IV adenosine, limiting the relevance of the findings.
Patient Population and Subgroups
The trial population included adults with documented PSVT episodes, and while the demographics were reported, there were concerns about the representativeness due to a high proportion of Caucasian participants.
Care Pathway Integration
Etripamil is designed for at-home use with clear instructions for self-administration, fitting well into existing care pathways for acute PSVT management, although some training may be required for proper use.
Resource Use and Cost Implications
There is a lack of data on direct medical costs and implementation costs, with only modeled budget impacts available, which do not provide a clear picture of the resource implications of etripamil.
Evidence Quality and Robustness
The evidence base is primarily derived from well-designed phase 3 trials with randomized, double-blind methodologies, although there are limitations regarding the completeness of episode confirmation.
Uncertainty, Sensitivity, and Broader Impacts
While some sensitivity analyses were conducted, the overall uncertainty regarding economic implications and the lack of equity analyses indicate significant concerns that could affect broader access and implementation.
